1,448.30
+0.04%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Venus Remedies
Its shares trade on NSE under the ticker VENUSREM.NS. It has been listed since 15 February 1995. In the fiscal year to 31 March 2026, it reported revenue of ₹7.70bn and net income of ₹1.03bn. At that date it held total assets of ₹8.54bn and shareholders' equity of ₹6.64bn.
Venus Remedies Ltd. engages in the manufacture and trade of pharmaceutical products. The company is headquartered in Panchkula, Haryana. The firm is a global injectable manufacturer, possessing a wide product basket catering to therapeutic segments of anti-infective specially in antimicrobial resistance (AMR), oncology, skin and wound care and pain management. The firm operates in the Pharmaceutical Formulation segment. The company manufactures products catering to the critical care and super specialty segments. The firm's product portfolio includes formulations such as injectables, tablets, and topical preparations. The firm offers solutions in the domains of antimicrobial resistance (AMR), oncology, skin & wound care, neurology, anticoagulants, pain management, herbal portfolio and disinfectants. Its focus therapy areas include medicine, surgery, neuro and orthopedics. The Company’s brands include Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, Ventaful and Nervolize. The company has three manufacturing facilities.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 15 Feb 1995
- Employees
- 998
- Website
- venusremedies.com ↗
Leadership
Pay as last reported
- Mr. Pawan ChaudharyChairman of the Board, Chief Financial Officer, Managing Director, since 2021₹12.1m
- Ms. Neha KodanCompliance Officer, Company Secretary, since 2011
- Dr. Manu ChaudharyJoint Managing Director, Whole Time Director₹12.0m
- Mr. Peeyush JainDeputy Managing Director, Whole-Time Director, since 1999₹7.4m
- Mr. Akshansh ChaudharyAdditional Whole Time Director, since 2022
- Mr. Ashutosh JainWhole-time Executive Director, since 2007₹6.8m
- Dr. Savita GuptaAdditional Non-Executive Independent Director₹10,000
- Dr. Anil KumarNon-Executive Independent Director
- Mr. Nps MongaAdditional Non-Executive Independent Director
- Mr. Jagdish SharmaNon-Executive Independent Director
- Mr. Navdeep SudAdditional Non-Executive Independent Director₹40,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Global injectable manufacturer with wide product basket in anti-infective and AMR segments.
- Manufactures critical care and super specialty formulations including injectables and tablets.
- Operates three manufacturing facilities in Panchkula, Haryana, supporting global supply.
Weaknesses
- Limited focus on non-critical care therapeutic areas beyond current portfolio.
- Reliance on specific product lines like Potentox and Vancoplus Combi for market presence.
- No mention of digital health or e-commerce strategies in business description.
Opportunities
- Expansion into emerging markets for antimicrobial resistance solutions in Asia-Pacific.
- Growing demand for oncology and skin & wound care products globally.
- Increased focus on herbal portfolio and disinfectants in post-pandemic healthcare.
Threats
- Intensifying competition in global injectable manufacturing sector.
- Regulatory challenges in pharmaceutical formulation segments worldwide.
- Potential supply chain disruptions affecting manufacturing facilities in Panchkula.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.